| Home | Free Articles for Your Site | Submit an Article | Advertise | Link to Us | Search | Contact Us |
This site is an archive of old articles


vertical line

JuvÉderm™ Experience Trial (JET)

As the aging population continues to increase, so also does the demand for non-invasive means for treating facial aging. To meet this need, Allergan, the makers of BOTOX Cosmetic, recently introduced the latest Hyaluronic Acid product to reach the market since Restylane.

The FDA approved both JUVÉDERM™ ULTRA and JUVÉDERM™ ULTRA PLUS in June 2006 following years of positive buzz from the European community. Both products are composed of Hyaluronic acid—a naturally occurring compound found within the various tissues of our body and responsible for maintaining cell hydration, joint lubrication, and a number of other biologic functions. Because of Hyaluronic Acid’s unique ability to bind as much as 1000 times its weight in water, it acts as a natural lubricant within our bodies. As we age, we lose this precious substance leaving our skin, our joints, and our eyes drier and more susceptible to age-related deterioration. When injected into the skin’s dermal layer, it binds water and functions as a plumping agent to restore lost volume.

Technological advancements have allowed Allergan to produce JUVÉDERM™ using a proprietary, technologically advanced formulation which allows it to contain the highest concentration of non-animal Hyaluronic Acid of any dermal filler currently available. This high concentration can then produce dramatic improvement in facial wrinkles and folds lasting up to six months or longer.

To introduce JUVÉDERM™, Allergan developed the JUVÉDERM™ Experience Trial (JET). This multi-center, open-label, non-comparison trial was recently unveiled to top North American physician injectors at Allergan’s 2006 National Education Faculty Meeting in Orange County, CA. Member’s of the Allergan NEF were introduced to the product, its long history of safety and efficacy, and educated to the JET trial. Beginning October 1, 2006 these injectors will be given pre-release access to JUVÉDERM™ and asked to enroll a total of 6 patients—all of whom must have had treatment by Restylane to their nasolabial folds at least 6 months prior. The second stipulation is that the filler product has to have completely dissipated. Patients will then receive a complimentary treatment with JUVÉDERM™ and will be asked to grade their experience with the product for the next 7 months. JUVÉDERM™ will then be released to the general injector public in January of 2007 with the results of the trial being published later that year.

“We are pleased to announce the availability of JUVÉDERM™ ULTRA and JUVÉDERM™ ULTRA PLUS as they join BOTOX® Cosmetic and our physician-dispensed skincare treatments in Allergan’s facial aesthetics portfolio,” said Robert Grant, Allergan Corporate Vice President and President of Inamed, a division of Allergan. “We believe the unique scientific benefits of JUVÉDERM™, along with its technologically advanced smooth formulation will establish the brand as a leader alongside BOTOX® Cosmetic in Allergan’s Total Facial Rejuvenation™ offering.”

Submitted by:

Body By Buford

Denver Cosmetic Surgeon




ARTICLE CATEGORIES

Aging
Arts and Crafts
Auto and Trucks
Automotive
Business
Business and Finance
Cancer Survival
Classifieds
Computers and Internet
Education
Family
Finances
Food and Drink
Gadgets and Gizmos
Gardening
Health
Hobbies
Home Improvement
Home Management
Humor
Jobs
Kids and Teens
Leadership
Legal
Legal B
Marketing
Men
Music and Movies
Online Business
Parenting
Pets and Animals
Politics and Government
Recreation and Sports
Relationships
Religion and Faith
Self Improvement
Site Promotion
Travel and Leisure
Travel Part B
Web Development
Women
Writing



http://www.articlesurfing.com/medical_business/juvéderm™_experience_trial_jet.html
Copyright © 1995-2016 Photius Coutsoukis (All Rights Reserved).